Clinical trial
Desensitization of Immunomodulating Agent-Related Hypersensitivity Reactions as a Means to Provide Therapeutic Options in the Management of Plasma Cell Disorders (DeHyperPCD)
NCT03959358 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Desensitization of Immunomodulating Agent-Related Hypersensitivity Reactions as a Means to Provide Therapeutic Options in the Management of Plasma Cell Disorders (DeHyperPCD)
- Lead sponsor
- University Health Network, Toronto
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 3, 2020
- Completion date
- October 7, 2022
- Enrollment
- 10 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.